Concepedia

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

Sergio Ricci, Giuseppe Boni, Ilaria Pastina, Dario Genovesi, Claudia Cianci, Serena Chiacchio, Cinzia Orlandini, M Grosso, Abedallatif AlSharif, Aldo Chioni,

European Journal of Nuclear Medicine and Molecular Imaging · 2007 · 61 citations · 27 references

DOI

Concepts

References

27

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

, , +12

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

, , +13

Cancer Statistics, 2003

Ahmedin Jemal, Thomas S. Murray, Alicia Samuels et al. · CA A Cancer Journal for Clinicians · 2003 · 3.3K citations · Full text

, , +17

Natural History of Progression After PSA Elevation Following Radical Prostatectomy

Charles R. Pound · JAMA · 1999 · 3.1K citations

, , +7

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations

, , +17